QUOTE AND NEWS
StreetInsider.com  Jul 21  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29+Enters+into+BELVIQ+Marketing+Agreement+in+Israel/9674520.html for the full story.
SeekingAlpha  Jul 18  Comment 
By Spencer Osborne: This week, we saw an anticipated pop in prescription numbers for the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ:ARNA). A nice week-over-week climb was expected, considering that the last data we saw fell in...
SeekingAlpha  Jul 16  Comment 
By Spencer Osborne: Arena Pharmaceuticals (NASDAQ:ARNA) has announced that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor Modulators" by the United States Patent and Trademark Office, for APD371, an agonist of the...
Motley Fool  Jul 15  Comment 
It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.
StreetInsider.com  Jul 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29+Confirms+USPTO+Issued+Patent+for+APD371/9662739.html for the full story.
Motley Fool  Jul 10  Comment 
Today's top stories in biotech and health care.
Motley Fool  Jul 10  Comment 
SeekingAlpha  Jul 7  Comment 
By Spencer Osborne: Sales of Arena Pharmaceuticals (ARNA) prescription anti-obesity drug Belviq are in and are okay this week. However, the focus of the week has shifted from script sales to a sale of shares by the CEO of the company, and that...
TheStreet.com  Jul 7  Comment 
NEW YORK (TheStreet) -- Arena Pharmaceuticals shares are plummeting, down -8.1% to $5.37, on Monday after CEO Jack Lief sold 223,525 shares of the company at an average price $5.85 for a total transaction of $1,307,621.25, according to an SEC...
Benzinga  Jul 7  Comment 
Arena Pharmaceuticals (NASDAQ: ARNA) shares plunged Monday on news that its chief executive Jack Lief sold nearly 40 percent of his holdings in the company. Lief sold 223,525 shares on July 1 at $5.85 per share. The transaction was an...
Benzinga  Jul 7  Comment 
GT Advanced Technologies (NASDAQ: GTAT) dropped 8.26% to $17.88 in pre-market trading. Canaccord Genuity downgraded GT Advanced from Buy to Hold. Central European Media Enterprises (NASDAQ: CETV) shares declined 3.18% to $2.74 in pre-market...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki